1Eady breast cancer trialists' collaborative croup. Lancet, 1999; 352: 930-947.
2Fishes ER, Wang J, Bryant J. Pathobiology of preoperative chemotherapy. Cancer, 2002; 95: 681-95.
3Youqing, Lixu, Xiaowei Sun. Affection of neoadjuvant chemotherapy on cell apoptosis and proliferation in breast cancer. US Chin, J Lymphology Oncology, 2002; 1: 53-55.
4Magno WB, Hirschfield L, Bhuign T. Correlation of proliferative index (PCNA reactivity and Ki.-67 reactivity) in primary breast carcinoma with hormone status, lymph node status and disease-flee survival. Conn Med, 1992; 56: 667-669.
5Swain SM, Sorace RA, Bagley CS. Neoed juvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer. Cancer Res, 1997; 47: 3889-3894.
6Blum JL, Jones SE, Buxder AU. Multicenter. Phase Ⅱ study of capecitabine in paclitxel-refractoty metastatic breast cancer. J Oncol, 1999; 17: 485-493.
7Rivera E, Brambs HJ, Gabelmann A. Phase I study of eniluracil and oral 5-flurouracil in combination with docetaxd in the treatment of patients with metastatic breast carcinoma. Cancer, 2002; 94:2321-2326.
8Vincent-Salomon, Jouve M, Genin PA. HER2 status in patients with breast carcinoma is not modified selectivdy by preoperative chemotherapy and is stable during the metastatic process. Cancer, 2002; 94: 2169-2173.
9Wang J, Bubholz TA, Middleton LP. Long-tenn outcome of neoadjuvant therapy for locally advanced breast carcinoma: effective clinical downstaging allows breast preservation and predicts outstanding locally control and survival. Cancer, 2002; 94: 3107-3114.
10Rieber A, Brambs HJ, Gabelmann A. Assesment of histologic features and expression of biomarkers in predicting pathologic response to anthracycline-based neoad juvant chemotherapy in patients with breast caarcinoma. Eur Radiol , 2002; 12: 1711-1719.
